紫杉醇联合索拉非尼治疗原发性肝癌的临床观察(1)
【摘要】 目的：探讨紫杉醇联合索拉非尼治疗原发性肝癌的临床效果。方法：选择2015年1月-
2016年1月就诊于本院的96例原发性肝癌患者，按随机数字表法分为A组(n=48)与B组(n=48)。A组采用口服索拉非尼、替吉奥治疗，B组采用紫杉醇联合索拉非尼治疗。比较两组临床疗效、肝功能、不良反应及生存率。结果：B组治疗总有效率为70.83%高于A组的47.92%(P<0.05);B组白蛋白(Albumin，ALB)水平高于A组(P<0.05)，B组谷丙转氨酶(alanine aminotransferase，ALT)与总胆红素(total bilirubin，TBIL)均低于A组(P<0.05);两组不良反应发生率比较，差异无统计学意义(P>0.05);B组1年生存率略高于A组，但差异无统计学意义(P>0.05);B组2、3年生存率分别为72.92%、41.67%均高于A组的43.75%、16.67%(P<0.05)。结论：紫杉醇联合索拉非尼可有效改善原发性肝癌患者病情，减轻对肝功能损害，提高生存率且不会增加不良反应，安全性较高。
【关键词】 原发性肝癌; 紫杉醇; 索拉非尼; 肝功能; 替吉奥
Clinical Observation of Paclitaxel Combined with Sorafenib in the Treatment of Primary Liver Cancer/FANG Yangyang，JING Hongying.//Medical Innovation of China，2019，16(23)：0-071
【Abstract】 Objective：To investigate the clinical effect of paclitaxel combined with sorafenib in the treatment of primary liver cancer.Method：96 patients with primary hepatocellular carcinoma admitted to our hospital from January 2015 to January 2016 were randomly divided into group A(n=48)and group B(n=48).Group A was treated with oral Sorafenib and Tegafur，Gimeracil and Oteracil Potassium Tablets，while group B was treated with Paclitaxel and Sorafenib.The clinical efficacy，liver function，adverse reactions and survival rate were compared between the two groups.Result：The total effective rate of group B was 70.83% higher than 47.92% of the group A(P<0.05).The level of albumin(ALB)in group B was higher than that of group A(P<0.05)，the level of alanine aminotransferase(ALT)and total bilirubin(TBIL)were lower than those of group A(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).
1 year survival rate in group B was slightly higher than that in group A，with no statistically significant difference(P>0.05).2，3 years survival rates in group B were 72.92% and 41.67%，higher than 43.75% and 16.67% in group A(P<0.05).Conclusion：Paclitaxel combined with Sorafenib can effectively improve the condition of patients with primary hepatocellular carcinoma，alleviate the damage to liver function，improve the survival rate without increasing adverse reactions，and has high safety.
【Key words】 Primary liver cancer; Paclitaxel; Sorafenib; Liver function; Tegafur，Gimeracil and Oteracil Potassium Tablets
First-author’s address：Jiamusi Infectious Diseases Hospital，Jiamusi 154007，China
doi：10.3969/j.issn.1674-4985.2019.23.017
原發性肝癌具有症状隐匿、高患病率、潜伏期长等特点，是指发生于肝脏上皮或间叶组织的恶性肿瘤，死亡率仅次于胃癌与肺癌[1]。多数原发性肝癌患者就诊时已发展为中晚期，错失手术治疗最佳时机。索拉非尼属于多靶点酪氨酸激酶抑制剂，可阻断内皮血管生长因子受体、Raf丝氨酸/苏氨酸激酶、碱性成纤维细胞生长因素、血小板衍生生长因子等活性，抑制肿瘤细胞繁殖与血管增生[2-3]。但单一使用有效率仅为15%～19%，需联合用药。紫杉醇属于抗微管药物，抑制纺锤丝形成，阻碍细胞G2/M期有丝分裂，促进细胞凋亡，被广泛应用于卵巢癌、乳腺癌等恶性肿瘤治疗[4-5]。替吉奥属于氟尿嘧啶衍生物，是一种前景乐观的抗肝癌药物，其毒副反应可耐受，对多种肿瘤治疗效果较好[6-7]。本研究选择2015年1月-2016年1月就诊于本院的96例原发性肝癌患者为研究对象，分析对原发性肝癌行替吉奥或紫杉醇联合索拉非尼治疗效果。现报道如下。, 百拇医药(方阳阳 荆洪英)
2016年1月就诊于本院的96例原发性肝癌患者，按随机数字表法分为A组(n=48)与B组(n=48)。A组采用口服索拉非尼、替吉奥治疗，B组采用紫杉醇联合索拉非尼治疗。比较两组临床疗效、肝功能、不良反应及生存率。结果：B组治疗总有效率为70.83%高于A组的47.92%(P<0.05);B组白蛋白(Albumin，ALB)水平高于A组(P<0.05)，B组谷丙转氨酶(alanine aminotransferase，ALT)与总胆红素(total bilirubin，TBIL)均低于A组(P<0.05);两组不良反应发生率比较，差异无统计学意义(P>0.05);B组1年生存率略高于A组，但差异无统计学意义(P>0.05);B组2、3年生存率分别为72.92%、41.67%均高于A组的43.75%、16.67%(P<0.05)。结论：紫杉醇联合索拉非尼可有效改善原发性肝癌患者病情，减轻对肝功能损害，提高生存率且不会增加不良反应，安全性较高。
【关键词】 原发性肝癌; 紫杉醇; 索拉非尼; 肝功能; 替吉奥
Clinical Observation of Paclitaxel Combined with Sorafenib in the Treatment of Primary Liver Cancer/FANG Yangyang，JING Hongying.//Medical Innovation of China，2019，16(23)：0-071
【Abstract】 Objective：To investigate the clinical effect of paclitaxel combined with sorafenib in the treatment of primary liver cancer.Method：96 patients with primary hepatocellular carcinoma admitted to our hospital from January 2015 to January 2016 were randomly divided into group A(n=48)and group B(n=48).Group A was treated with oral Sorafenib and Tegafur，Gimeracil and Oteracil Potassium Tablets，while group B was treated with Paclitaxel and Sorafenib.The clinical efficacy，liver function，adverse reactions and survival rate were compared between the two groups.Result：The total effective rate of group B was 70.83% higher than 47.92% of the group A(P<0.05).The level of albumin(ALB)in group B was higher than that of group A(P<0.05)，the level of alanine aminotransferase(ALT)and total bilirubin(TBIL)were lower than those of group A(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).
1 year survival rate in group B was slightly higher than that in group A，with no statistically significant difference(P>0.05).2，3 years survival rates in group B were 72.92% and 41.67%，higher than 43.75% and 16.67% in group A(P<0.05).Conclusion：Paclitaxel combined with Sorafenib can effectively improve the condition of patients with primary hepatocellular carcinoma，alleviate the damage to liver function，improve the survival rate without increasing adverse reactions，and has high safety.
【Key words】 Primary liver cancer; Paclitaxel; Sorafenib; Liver function; Tegafur，Gimeracil and Oteracil Potassium Tablets
First-author’s address：Jiamusi Infectious Diseases Hospital，Jiamusi 154007，China
doi：10.3969/j.issn.1674-4985.2019.23.017
原發性肝癌具有症状隐匿、高患病率、潜伏期长等特点，是指发生于肝脏上皮或间叶组织的恶性肿瘤，死亡率仅次于胃癌与肺癌[1]。多数原发性肝癌患者就诊时已发展为中晚期，错失手术治疗最佳时机。索拉非尼属于多靶点酪氨酸激酶抑制剂，可阻断内皮血管生长因子受体、Raf丝氨酸/苏氨酸激酶、碱性成纤维细胞生长因素、血小板衍生生长因子等活性，抑制肿瘤细胞繁殖与血管增生[2-3]。但单一使用有效率仅为15%～19%，需联合用药。紫杉醇属于抗微管药物，抑制纺锤丝形成，阻碍细胞G2/M期有丝分裂，促进细胞凋亡，被广泛应用于卵巢癌、乳腺癌等恶性肿瘤治疗[4-5]。替吉奥属于氟尿嘧啶衍生物，是一种前景乐观的抗肝癌药物，其毒副反应可耐受，对多种肿瘤治疗效果较好[6-7]。本研究选择2015年1月-2016年1月就诊于本院的96例原发性肝癌患者为研究对象，分析对原发性肝癌行替吉奥或紫杉醇联合索拉非尼治疗效果。现报道如下。, 百拇医药(方阳阳 荆洪英)